Noteworthily, the uncertainty in the quality of blood-derived products can bring many risks to the treatment of T2DM; for example, the glycated HSA has negative effects on patients and limits the value of blood-derived HSA in the treatment of T2DM [13]. This evidence concerns the gene ALB and type 2 diabetes mellitus.